Conyers advises Hony Capital Fund V and New Good Management on privatisation of Simcere
Conyers Dill & Pearman has advised Hony Capital Fund V and New Good Management on the $495m (£300m) privatisation of Simcere Pharmaceutical Group from the New York Stock Exchange (NYSE) by way of merger.
Simcere is a pharmaceutical company specialising in the development, manufacture and marketing of branded and proprietary pharmaceuticals in China.
Conyers co-chair David Lamb and associate Angie Chu, both based in Conyers’ Hong Kong office, acted in this matter. They worked alongside Cleary Gottlieb Steen & Hamilton and Shearman & Sterling.
News from Conyers Dill & Pearman
Briefings from Conyers Dill & Pearman
International co-operation in cross-border insolvencies: smoothing the path for foreign liquidators in Hong Kong
A decision of the High Court of the Hong Kong SAR should make the task of liquidators of BVI, Cayman and other foreign companies more straightforward in the region.
The BVI Arbitration Act 2013 will come into force on 1 October 2014.